Because Ell3 is an additional factor to the triple complex of ER(α), GATA3 and FOXA1 and this complex fine-tunes the expression level of IL-20, it will be essential to assess the clinical meaning of the expression of FOXA1 in combination with the expression of Ell3 in ER(α) breast cancer patients. This evidence concerns the gene FOXA1 and breast cancer.